Difference between revisions 600899173 and 605853696 on enwiki

'''Zerona''' is a low-level laser device developed by Erchonia Corp. for non-invasive body slimming of the waist, hips, and thighs. It has been shown to disrupt [[adipocyte]], or fat cell, membranes causing the release of stored [[lipids]] and fatty material, in turn, promoting adipocyte collapse. The device was first introduced to the market in 2008 as an [[off-label use]] device for slimming, but later was granted 510k market clearance by the [[Food and Drug Administration]] (contracted; show full)eeks one and two, and a two-week post-procedure follow-up measurement. After two weeks the active treatment group averaged a cumulative reduction of 3.54&nbsp;inches compared to the control group which averaged a cumulative reduction of just 0.68&nbsp;inches. At the two-week post-procedure follow-up, active group participants did not exhibit a significant gain in their measurements. No adverse events or side-effects were reported during the clinical trial.<ref name=pmid20014253/>

== Ongoing 
Rresearch ==
The adipocyte or fat cell is described as an endocrine organ cell responsible for the synthesis of bioactive peptides which participate in autocrine, paracrine, and endocrine pathways.  The physical adaptability of the adipocyte is extraordinary, enabling it to expand nearly 1,000 fold in volume and 10 fold in diameter in order to store excessive fuel as triglycerides.<ref>{{cite journal |pmid=9843879 |year=1998 |last1=Marques |first1=BG |last2=Hausman |first2=DB |last3=Martin |first3=RJ |t(contracted; show full)

Adipocyte [[hypertrophy]] has been shown to directly disrupt [[angiogenesis]], [[adipogenesis]], extracellular matrix dissolution and reformation, lipogenesis, growth factor production, glucose metabolism, lipid metabolism, enzyme production, immune response, and hormone production.<ref name=pmid17021375>{{cite journal |pages=242S–
249S |doi=10.1038/oby.2006.317 |title=Adipose Tissue as an Endocrine Organ |year=2006 |last1=Ahima |first1=Rexford S. |journal=Obesity |volume=14 |pmid=17021375}}</ref> Furthermore, studies have illustrated an alteration in [[gene expression]] recording an upregulation in [[proinflammatory]] factors including classic [[cytokines]] and [[complement factors]].<ref name=pmid17021375/><ref name=pmid18473870>{{cite journal |pmid=18473870 |year=2008 |last1=Heilbronn |first1=LK |last2=Campbell |fir(contracted; show full)e journal |first1=Robert F. |last1=Jackson |first2=Greg C. |last2=Roche |first3=Kevin |last3=Wisler |year=2010 |title=Reduction in Cholesterol and Triglyceride Serum Levels Following Low-Level Laser Irradiation: A Noncontrolled, Nonrandomized Pilot Study |journal=The American Journal of Cosmetic Surgery |volume=27 |issue=4 |pages=177–84 |url=http://www.erchonia.com/files/uploads/1/file/Jackson_Reduction%20in%20Cholesterol%20and%20Triglyceride%20Serum%20Levels%20Following%203LT_AJCS_2010.pdf}}</ref>


== References ==
{{reflist|2}}⏎
⏎
==External links==
*  [http://www.erchonia.com/ Erchonia Corp., Official Website]

== References ==
{{reflist|2}}⏎
⏎
[[Category:Laser medicine]]
[[Category:Management of obesity]]